BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 15739020)

  • 41. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
    Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
    Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The expression of ER beta protein correlates with vascular endothelial growth factor and its prognostic significance in human breast cancer.
    Wen XF; Shen Z; Shen ZZ; Nguyen M; Shao ZM
    Oncol Rep; 2002; 9(5):937-44. PubMed ID: 12168051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cancer of the breast and the receptor status].
    Buonomo O; Serao A; Muggianu A; Guglielmelli E; Davoli E; Amori A
    G Chir; 1991 Apr; 12(4):274-7. PubMed ID: 1911078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
    Iwase H; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Toyama T; Hara Y; Kobayashi S
    Cancer Detect Prev; 1997; 21(1):29-35. PubMed ID: 9043760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.
    Göhring UJ; Ahr A; Scharl A; Weisner V; Neuhaus W; Crombach G; Holt JA
    J Soc Gynecol Investig; 1995; 2(4):653-9. PubMed ID: 9420872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Independent prognostic value of laminin receptor expression in breast cancer survival.
    Marques LA; Franco EL; Torloni H; Brentani MM; da Silva-Neto JB; Brentani RR
    Cancer Res; 1990 Mar; 50(5):1479-83. PubMed ID: 2137368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer.
    Zegarac M; Nikolic S; Gavrilovic D; Jevric M; Kolarevic D; Nikolic-Tomasevic Z; Kocic M; Djurisic I; Inic Z; Ilic V; Santrac N
    J BUON; 2013; 18(4):859-65. PubMed ID: 24344009
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I-III of operable patients.
    Gao D; Du J; Cong L; Liu Q
    Jpn J Clin Oncol; 2009 Feb; 39(2):97-104. PubMed ID: 19052036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
    Keshgegian AA; Cnaan A
    Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ; Cui X; Hilsenbeck SG; Lee AV
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
    Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.